Toll Free: 1-888-928-9744

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Pipeline Review, H2 2016', provides in depth analysis on Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1)
- The report reviews Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Overview 6 Therapeutics Development 7 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Stage of Development 7 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Therapy Area 8 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Indication 9 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Companies 12 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Universities/Institutes 14 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Companies Involved in Therapeutics Development 22 Arrien Pharmaceuticals, LLC 22 Bionomics Limited 23 Novartis AG 24 OncoTherapy Science, Inc. 25 Selvita S.A. 26 SignalChem Lifesciences Corp 27 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Drug Profiles 28 ARN-7016 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Drugs to Inhibit MELK for Solid Tumors - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 OTS-167 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 SEL-128 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Small Molecules to Inhibit MELK for Oncology - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Small Molecules to Inhibit MELK for Oncology - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Vaccine to Target FOXM1, MELK, HJURP, VEGFR-1 and VEGFR-2 for Ovarian Cancer - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Dormant Projects 36 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Featured News & Press Releases 37 Mar 17, 2016: The Phase I clinical study of OTS167, MELK specific inhibitor, in Australia Completed 37 Feb 29, 2016: Publication of a paper describing the possible effect of a MELK inhibitor OTS167 on kidney cancer 37 Feb 26, 2016: Publication for possible biomarkers of OTS167, MELK inhibitor 38 Feb 12, 2016: Publication of a paper describing the possible effect of a MELK inhibitor, OTS167, on small cell lung cancer 38 Jan 25, 2016: The commencement of Phase I/II clinical study of OTS167, MELK specific inhibitor, for Acute Myeloid Leukemia patients in USA 38 Jan 05, 2016: MELK inhibitor, OTS167, Phase I clinical study commencement in Australia 39 Jun 18, 2015: The commencement of patient enrollment in Phase I clinical study of OTS167, a novel small molecule compound targeting cancer stem cells 39 Apr 15, 2013: Selvita Reports Data from SEL128 Oncology Program At AACR Annual Meeting 2013 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 41 Disclaimer 42
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Assessment by Monotherapy/Combination Products, H2 2016 16 Number of Products by Stage and Mechanism of Action, H2 2016 17 Number of Products by Stage and Route of Administration, H2 2016 19 Number of Products by Stage and Molecule Type, H2 2016 21 Pipeline by Arrien Pharmaceuticals, LLC, H2 2016 22 Pipeline by Bionomics Limited, H2 2016 23 Pipeline by Novartis AG, H2 2016 24 Pipeline by OncoTherapy Science, Inc., H2 2016 25 Pipeline by Selvita S.A., H2 2016 26 Pipeline by SignalChem Lifesciences Corp, H2 2016 27 Dormant Projects, H2 2016 36



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $3500
Multi User - US $7000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify